drugset

drugset / Trial / NCT06123468

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

NCT06123468 ↗

Phase 1/2 Completed 58 enrolled Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Gilead Sciences · collab

NaSingle-groupOpen-labelTreatment

Summary

The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma

Timeline

Start: 2024-04-17
Primary completion: 2026-01-07
Completion: 2026-01-07

Publications

Kobitzsch B, Stocker G, Hacker UT, Junge S, Pauligk C, Al-Batran SE, Goetze TO, Lordick F. SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma. ESMO Gastrointest Oncol. 2024 Apr 12;4:100051. doi: 10.1016/j.esmogo.2024.100051. eCollection 2024 Jun.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sacituzumab Govitecan	Monoclonal antibody	10 mg/kg	Intravenous

Indications